ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Digging In The Dirt Yields Novel Bacteria Fighter

Antibiotics: Researchers isolated antibacterial compound teixobactin from so-called unculturable bacteria

by Bethany Halford
December 21, 2015 | APPEARED IN VOLUME 93, ISSUE 49

[+]Enlarge
Teixobactin.
Teixobactin.

COVER STORY

Digging In The Dirt Yielded Novel Bacteria Fighter

Many of the antibiotics doctors prescribe to fight bacterial infections were first unearthed as the products of microorganisms in the soil. But only about 1% of environmental microorganisms will grow in a laboratory petri dish. The other 99% are considered unculturable. Wondering what treasure trove of useful compounds might be waiting to be discovered, researchers led by biologist Kim Lewis at Northeastern University developed a screening method that coaxes unculturable bacteria to grow. Lewis and his team add small amounts of bacteria to a culturing device called an iChip, place the gadget between two semipermeable membranes, and then bury it all in the soil for a week or two. Using this method, the researchers discovered the bacteria-fighting compound called teixobactin (Nature 2015, DOI: 10.1038/nature14098). The compound, a macrocyclic depsipeptide, represents a new class of bacteria fighters because it is a potent killer of gram-positive pathogens and is effective against methicillin-resistant Staphylococcus aureus and Streptococcus pneumonia in mice. Although there are a handful of new classes of antibiotics in the pipeline, the last antibiotic from a new class to be approved by FDA was Sirturo (bedaquiline), a narrow-spectrum tuberculosis fighter discovered in 1997. Lewis’s team reports that teixobactin’s novel mechanism of action makes it tough for bacteria to develop resistance to the compound. “We have sent teixobactin to a large number of laboratories, including those specifically aimed at obtaining resistant mutants. No mutants so far,” Lewis tells C&EN. The compound is currently in preclinical development with NovoBiotic Pharmaceuticals, a company that was part of the compound’s discovery.

[+]Enlarge
Credit: TK
Discovery of antibacterial classes has fallen off in recent decades.
Credit: TK
Discovery of antibacterial classes has fallen off in recent decades.
X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment